Faculty Information - IKEDA Takashi

（Last updated : 2025-12-12 14:47:47）

IKEDA Takashi
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Impact of prolonged warm ischemia during clamped partial nephrectomy: Comparison between Japanese and American cohorts. 2025/12
2.	Case report	Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report 2025/09/01
3.	Original article	Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
4.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
5.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
6.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
7.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
8.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
9.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
10.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
11.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
12.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
13.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
14.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
15.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
16.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
17.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
18.	Original article	Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
19.	Case report	Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. 2016/07
Display 5 items
Display all(19)

■ Academic conference presentation

1.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （ポスター掲示，一般） 2024/05/03
2.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （ポスター掲示） 2024/04/26
3.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （ポスター掲示） 2024/04/26
4.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （ポスター掲示） 2024/04/26
5.	A novel method for ex vivo stimulation of mesenchymal stem cells via invariant natural killer T cell activation with ɑ-galactosylceramide. （ポスター掲示，一般） 2022/06/05
6.	Predictive factors related to the number of TUL for kidney stones in our hospital. （ポスター掲示，一般） 2020/12/22
7.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. （ポスター掲示，一般） 2020/10/01
8.	Long-term follow-up of renal function and development of chronic kidney disease after partial nephrectomy. （ポスター掲示，一般） 2019/05/04
9.	Usefulness of the modified Glasgow Prognostic Score (mGPS) in patients with castration- sensitive prostate cancer: muti- institutional study. （ポスター掲示） 2018/04/19
10.	The risk factor of renal scarring in the myelomeningocele patients in early phase. （ポスター掲示，一般） 2016/04/23
11.	The role of routine urine cultures in children with spina bifida using clean intermittent catheterization. （ポスター掲示，一般） 2016/04/23
Display 5 items
Display all(11)